Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Genentech/Constellation, Bayer/Ventana, Genzyme/Veracyte

Executive Summary

Epigenetics took the spotlight this week, with Genentech being the latest pharma to move into the field in partnership with Constellation Pharmaceuticals. In other deals, Bayer signed Ventana to develop a companion diagnostic, and Pfizer walked away from Medivation and Alzheimer’s drug Dimebon.

You may also be interested in...



Ventana President Mara Aspinall: An Interview With “The Pink Sheet” DAILY

In the midst of a busy January – in which Ventana has signed four publicly disclosed deals to develop companion diagnostics with pharma partners – Ventana President Mara Aspinall talked with “The Pink Sheet” DAILY about pharma’s evolving attitude on personalized medicine, sharing value for joint projects and how Ventana is positioning itself to be the partner of choice for pharma.

Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial

A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.

Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop

The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054126

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel